Business / Finance

RSS

AxoGen third quarter revenues increase 42.5% to $1.1 million

AxoGen, Inc. today reported third quarter of 2011 revenues of $1.1 million, a 42.5% increase over $0.8 million reported during the third quarter of 2010.

10 Nov 2011

Kanghui third quarter total net revenue increases 26.9% to RMB80.7M

China Kanghui Holdings, a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced financial results for the third quarter of 2011.

10 Nov 2011

LGL third quarter total revenues decrease 22.3% to $9,629,000

The LGL Group, Inc., announced results for the quarter ended September 30, 2011.

9 Nov 2011

BioSante third quarter net loss increases to $12.7 million

BioSante Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2011 and provided an update on the Company's pipeline.

9 Nov 2011

ACADIA third quarter revenues decrease to $584,000

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2011.

9 Nov 2011

Ventas to receive $125 million as lawsuit settlement from HCP

Ventas, Inc. today announced that HCP, Inc. has agreed to pay it $125 million to settle the Company's outstanding lawsuit against HCP arising out of the Company's 2007 acquisition of Sunrise Senior Living REIT.

9 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Accretive Health third quarter net services revenue increases 38% to $218.9 million

Accretive Health, Inc., a leading provider of comprehensive end-to-end healthcare revenue cycle management services and population health management services infrastructure, today announced financial results for the third quarter ended September 30, 2011.

9 Nov 2011

BioClinica third quarter service revenues increase 4.1% to $16.6 million

BioClinica, Inc., a global provider of clinical trial management and technology solutions, today announced its financial results for the third quarter and nine months ended September 30, 2011.

From Clario 9 Nov 2011

Salix to acquire Oceana Therapeutics

Oceana Therapeutics LLC, a privately owned global company focused on commercializing best-in-class specialty therapeutics, today announced it has entered into a definitive agreement for the sale of its operating subsidiary, Oceana Therapeutics, Inc. to Salix Pharmaceuticals, Ltd. of Raleigh, NC.

9 Nov 2011

Allied Healthcare first quarter sales decrease to $11.4 million

Allied Healthcare Products, Inc. reported a loss in its first quarter on a decline in sales.

9 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

BioMimetic Therapeutics reports third quarter total revenues of $0.4M

BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011.

9 Nov 2011

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity Pharmaceuticals, Inc. today highlighted its recent clinical and business progress and announced its third quarter 2011 financial results.

9 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

BioTime third quarter revenue increases 40% to $1.1 million

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.

9 Nov 2011